[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"msi-h-colorectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:msi-h-colorectal-cancer":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,61],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":40,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":60},"100618120","predicting-response-to-immunotherapy-from-analysis-of-live-tumor-biopsies-elephas-05-100618120",false,"NCT07327489","Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)","Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies","ELEPHAS-05","Inclusion Criteria:\n\n1. Able and willing to provide informed consent for participation\n2. Age ≥18 years at time of consent.\n3. Have a suspected or confirmed cancer diagnosis that is to be evaluated by means of a biopsy.\n4. Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment.\n\nExclusion Criteria:\n\n1. Have a known auto-immune disease or prior condition (prior organ transplant, chronic kidney or liver disease) that renders them ineligible for immunotherapy (IO) treatment.\n2. Severely immunocompromised person(s). Examples include patients on immunosuppressants, HIV positive patients on antiretrovirals, post transplantation patients.\n3. Pregnant person(s).","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","OBSERVATIONAL","This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39],"Cancer","Immunotherapy","Advanced Solid Tumors Cancer","Bladder Cancer","TNBC, Triple Negative Breast Cancer","Colorectal Cancer","DMMR Colorectal Cancer","MSI-H Colorectal Cancer","Endometrial Cancer","Head and Neck Cancer","Kidney Cancer","Liver Cancer","NSCLC (Non-small-cell Lung Cancer)","Skin Cancer","Melanoma (Skin Cancer)",[26,41,42,25,43,44,45,46,47,48],"Live Tumor Biopsy","Elephas","Imaging","Tumor Cutting","Treatment Response","Core Needle Biopsy","Forceps Biopsy","Punch Biopsy","RECRUITING","2026-06-25",{"date":52,"type":53},"2026-06-29","ACTUAL",{"date":55,"type":53},"2025-04-14",{"date":57,"type":21},"2038-04",{"name":42,"class":59},"INDUSTRY",8,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":4},"100503889","phase-2-tislelizumab-combined-with-chemotherapy-capox-in-the-perioperative-treatment-of-msi-hdmmr-stage-ii-or-iii-colorectal-cancer-100503889","NCT05841134","Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H\u002FdMMR Stage II or III Colorectal Cancer","Multicenter, Single-arm, Open-label Phase II Clinical Study of Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H\u002FdMMR Stage II or III Colorectal Cancer","Inclusion Criteria:\n\n1. ECOG: 0\\~1;\n2. Patients with colon or rectal adenocarcinoma confirmed by histology or cytology;\n3. The tissue specimens are confirmed as MSI-H by PCR or NGS. If the patients are dMMR by immunohistochemistry, they need to be confirmed as MSI-H by PCR (2021 Expert Consensus on Immunotherapy for Patients with Colorectal Cancer);\n4. Patients with clinical stage II or III (cT3-T4 N0 M0 or Tany N+M0, clinically positive lymph nodes are defined as any lymph node ≥ 1.0 cm);\n5. Expected survival period ≥ 12 weeks;\n6. The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with follow-up visits.\n\nExclusion Criteria:\n\n1. Have received anti-tumor therapy;\n2. Have received PD-(L)1 or CTLA-4 treatment;\n3. The patient has any active autoimmune disease or has a history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis , hyperthyroidism; patients with vitiligo; asthma that has been completely remitted in childhood and does not require any intervention in adulthood can be included; patients with asthma requiring medical intervention with bronchodilators cannot be included);\n4. Patients are using immunosuppressants or systemic hormone therapy to achieve the purpose of immunosuppression (dose\\>10mg\u002Fday prednisone or other equivalent hormones), and continue to use within 2 weeks before enrollment;\n5. Patients with any severe and\u002For uncontrolled diseases\n6. Urine routine prompts urine protein ≥ ++, and confirmed 24-hour urine protein quantity \\> 1.0g;\n7. Pregnant or lactating women;\n8. Patients with other malignant tumors within 5 years (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);\n9. Those who have a history of psychotropic drug abuse and cannot quit or patients with mental disorders;","75 Years",{"count":70,"type":21},25,"INTERVENTIONAL",[73],"PHASE2","This study is a multi-center, single-arm, open-label phase II clinical trial, aiming to observe and evaluate the perioperative treatment of tislelizumab combined with chemotherapy (CAPOX) in stage II or III colorectal cancer with MSI-H\u002FdMMR Patient efficacy and safety.",[32,76,77,78],"Tislelizumab","Oxaliplatin","Capecitabine","NOT_YET_RECRUITING","2023-05-05",{"date":82,"type":53},"2023-05-09",{"date":84,"type":21},"2023-06-01",{"date":86,"type":21},"2027-01-31",{"name":88,"class":89},"The First Affiliated Hospital of Zhengzhou University","OTHER"]